A Study to Evaluate the Effectiveness of MEDI-563 in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

Exclusion Criteria

• - Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
• - Pregnant, breastfeeding, or lactating women
• - Known history of allergy or reaction to any component of the investigational product formulation
• - History of anaphylaxis to any other biologic therapy
• - Donation or transfusion of blood, plasma or platelets within the past 3 months prior to Screening
• - Other significant pulmonary disease which in the opinion of the investigator or medical monitor, might compromise the interpretation of the study
• - Fever greater than (>) 37.0 degree Centigrade (98.6 degree Fahrenheit) at Screening
• - Receipt of any novel investigational medicinal product within 3 months before the first dose of investigational product in this study and through the end of the study
• - Seropositive for hepatitis A, hepatitis B surface antigen, hepatitis C, or human immunodeficiency virus 1or 2 (HIV-1 or HIV 2)
• - History of alcohol or drug abuse within the past year that required treatment that the investigator felt or medical monitor felt would compromise the study data interpretation
• - Past or current malignancy within the past 5 years except adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma in situ treated with apparent success more than 1 year prior to Screening
• - Subjects participating in, or scheduled for, an intensive COPD rehabilitation program (subjects who are in the maintenance phase of a rehabilitation program are eligible to take part)
• - Current diagnosis of asthma according to Global Initiative for Asthma guidelines
• - Previous treatment with MEDI-563.